Literature DB >> 32856234

Erenumab efficacy in chronic migraine and medication overuse: a real-life multicentric Italian observational study.

Francesca Schiano di Cola1, Renata Rao2, Salvatore Caratozzolo2, Marco Di Cesare2, Elisabetta Venturelli3, Ubaldo Balducci4, Vincenzo Sidoti4, Elisa Pari5, Chiara Costanzi5, Alfonsina di Summa6, Gabriele Johanna Sixt6, Elisabetta D'Adda7, Paolo Liberini2, Alessandro Padovani2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32856234     DOI： 10.1007/s10072-020-04670-5

Source DB:  PubMed          Journal:  Neurol Sci        ISSN： 1590-1874            Impact factor:   3.307


× No keyword cloud information.
  5 in total

1.  Erenumab Discontinuation After 12-Month Treatment: A Multicentric, Observational Real-Life Study.

Authors:  Francesca Schiano di Cola; Salvatore Caratozzolo; Elisabetta Venturelli; Ubaldo Balducci; Vincenzo Sidoti; Elisa Pari; Chiara Costanzi; Alfonsina di Summa; Gabriele Johanna Sixt; Elisabetta D'Adda; Paolo Liberini; Renata Rao; Alessandro Padovani
Journal:  Neurol Clin Pract       Date:  2021-12

2.  Real-world evidence data on the monoclonal antibody erenumab in migraine prevention: perspectives of treating physicians in Germany.

Authors:  Andreas Straube; Philipp Stude; Charly Gaul; Katrin Schuh; Mirja Koch
Journal:  J Headache Pain       Date:  2021-11-06       Impact factor: 7.277

3.  Long-Term Effectiveness of Three Anti-CGRP Monoclonal Antibodies in Resistant Chronic Migraine Patients Based on the MIDAS score.

Authors:  Luigi Francesco Iannone; Davide Fattori; Silvia Benemei; Alberto Chiarugi; Pierangelo Geppetti; Francesco De Cesaris
Journal:  CNS Drugs       Date:  2022-02-11       Impact factor: 5.749

Review 4.  Reducing the Burden of Migraine: Safety and Efficacy of CGRP Pathway-Targeted Preventive Treatments.

Authors:  George R Nissan; Richard Kim; Joshua M Cohen; Michael J Seminerio; Lynda J Krasenbaum; Karen Carr; Vincent Martin
Journal:  J Clin Med       Date:  2022-07-27       Impact factor: 4.964

5.  MAB-MIG: registry of the spanish neurological society of erenumab for migraine prevention.

Authors:  Robert Belvís; Pablo Irimia; Patricia Pozo-Rosich; Carmen González-Oria; Antonio Cano; Javier Viguera; Belén Sánchez; Francisco Molina; Isabel Beltrán; Agustín Oterino; Elisa Cuadrado; Angel Gómez-Camello; Miguel Alberte-Woodward; Carmen Jurado; Teresa Oms; David Ezpeleta; Javier Díaz de Terán; Noemí Morollón; Germán Latorre; Marta Torres-Ferrús; Alicia Alpuente; Raquel Lamas; Carlos Toledano; Rogelio Leira; Sonia Santos; Margarita Sánchez Del Río
Journal:  J Headache Pain       Date:  2021-07-17       Impact factor: 7.277
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.